A COMPREHENSIVE REVIEW ON COMPARISON OF GDOCP IN PHARMACEUTICAL MANUFACTURING UNIT AS PER EUROPEAN AND WHO GUIDELINES

Authors

  • MALE TEJASWI Department of Pharmaceutical Quality Assurance, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, Ananthapuramu 515001, AP, India
  • VINOD KUMAR K. Department of Pharmaceutical Analysis, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, Ananthapuramu 515001, AP, India
  • CHITHRA SHEKAR C. Department of Pharmaceutical Analysis, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, Ananthapuramu 515001, AP, India
  • SRIKANTH K. Department of Pharmaceutical Analysis, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, Ananthapuramu 515001, AP, India

DOI:

https://doi.org/10.22159/ijcpr.2021v13i4.42736

Keywords:

Good documentation practice, European union, World health organisation, Regulatory authorities

Abstract

To review the good documentation practices in the pharmaceutical industry as per the guidelines provided in the European Commission and WHO (World Health Organisation). GDocP is a systematic method of planning, evaluating, approving, issuing, documenting, preserving, and archiving records. GDocP is a must when operating in an atmosphere of existing GMP. To provide an overview of good documentation practices for those employed in the pharmaceutical and healthcare sectors. The GDocP stands for good documentation practice which can be described as an integral part of quality assurance (QA) and thus related to all aspects of GMP. There are very few articles related to the comparison of GDocP in the pharmaceutical manufacturing unit as per European and WHO guidelines hence we are trying to develop a study on the comparison of GDocP guidelines. Public and private organizations, institutions, and regulatory authorities working and cooperating and with the pharmaceutical industry are involved at the international and national level to reach a consensus on the guidelines and laws for the production of medicinal products for human. This article explains how these participants work and cooperate and set out current regulations along the lines of the European community and WHO referencing, where appropriate, the practiced guidelines, outside space regulatory action referred to above. In this way, the goal is to achieve exceptional standards of quality, protection, and efficacy in the manufacture of health products.

Downloads

Download data is not yet available.

References

1. Sandle T. Good documentation practices. J Valid Tech; 2014.
2. Bargaje C. Good documentation practice in clinical research. Perspectives Clin Res 2011;2:59.
3. Naidu RP. Causality assessment: a brief insight into practices in pharmaceutical industry. Perspectives Clin Res 2013;4:233.
4. Kumar K. Good documentation practices (GDPs) in pharmaceutical industry. J Anal Pharm Res 2017;4:00100.
5. Patel KT, Chotai NP. Documentation and records harmonized GMP requirements. J Young Pharma 2011;3:138-50.
6. Tairova KE, Dilbarkhanova JR, Rayisyan MG, Sekerin VD, Evgenievna A. Aspects of improving the regulatory system of pharmaceutical products in the republic of Kazakhstan. J Adv Pharm Edu Res 2020;10:87-92.
7. Patel LJ, Panjwani KR, Ray J. Review on good documentation practice in pharmaceutical manufacturing unit as per European Union GMP chapter-4 on documentation. Pharma Tutor 2019;7:1-4.
8. Patel KT, Chotai NP. Documentation and records: harmonized GMP requirements. J Young Pharm 2011;3:138-50.
9. McDowall RD. Data integrity and data governance: practical implementation in regulated laboratories. Royal Soc Chem 2018. https://doi.org/10.1039/9781788013277
10. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Meeting, World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fiftieth Report. WHO; 2016.

Published

15-07-2021

How to Cite

TEJASWI, M., V. K. K., C. S. C., and S. K. “A COMPREHENSIVE REVIEW ON COMPARISON OF GDOCP IN PHARMACEUTICAL MANUFACTURING UNIT AS PER EUROPEAN AND WHO GUIDELINES”. International Journal of Current Pharmaceutical Research, vol. 13, no. 4, July 2021, pp. 21-24, doi:10.22159/ijcpr.2021v13i4.42736.

Issue

Section

Review Article(s)